These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 9988373)
1. Mechanistic modeling of rodent liver tumor promotion at low levels of exposure: an example related to dose-response relationships for 2,3,7,8-tetrachlorodibenzo-p-dioxin. Andersen ME; Conolly RB Hum Exp Toxicol; 1998 Dec; 17(12):683-90; discussion 701-4, 708-18. PubMed ID: 9988373 [No Abstract] [Full Text] [Related]
2. Hepatic foci in rats after diethylnitrosamine initiation and 2,3,7,8-tetrachlorodibenzo-p-dioxin promotion: evaluation of a quantitative two-cell model and of CYP 1A1/1A2 as a dosimeter. Conolly RB; Andersen ME Toxicol Appl Pharmacol; 1997 Oct; 146(2):281-93. PubMed ID: 9344896 [TBL] [Abstract][Full Text] [Related]
3. Promotion of N-nitrosodiethylamine-initiated hepatocellular tumors and hepatoblastomas by 2,3,7,8-tetrachlorodibenzo-p-dioxin or Aroclor 1254 in C57BL/6, DBA/2, and B6D2F1 mice. Beebe LE; Fornwald LW; Diwan BA; Anver MR; Anderson LM Cancer Res; 1995 Nov; 55(21):4875-80. PubMed ID: 7585523 [TBL] [Abstract][Full Text] [Related]
4. Dose-response relationships for chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in a rat tumor promotion model: quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver. Tritscher AM; Goldstein JA; Portier CJ; McCoy Z; Clark GC; Lucier GW Cancer Res; 1992 Jun; 52(12):3436-42. PubMed ID: 1596902 [TBL] [Abstract][Full Text] [Related]
5. Modeling the number and size of hepatic focal lesions following exposure to 2,3,7,8-TCDD. Portier CJ; Sherman CD; Kohn M; Edler L; Kopp-Schneider A; Maronpot RM; Lucier G Toxicol Appl Pharmacol; 1996 May; 138(1):20-30. PubMed ID: 8658509 [TBL] [Abstract][Full Text] [Related]
6. Dose-response and risk assessment considerations for receptor-mediated effects: case study with a TCDD hepatic tumor promotion model. Sewall CH; Lucier GW Prog Clin Biol Res; 1994; 387():155-71. PubMed ID: 7972245 [No Abstract] [Full Text] [Related]
7. NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 2006 Apr; (521):4-232. PubMed ID: 16835633 [TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of enzyme-altered liver foci in rats initiated with diethylnitrosamine and promoted with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin. Moolgavkar SH; Luebeck EG; Buchmann A; Bock KW Toxicol Appl Pharmacol; 1996 May; 138(1):31-42. PubMed ID: 8658510 [TBL] [Abstract][Full Text] [Related]
9. Tumor-promoting effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and phenobarbital in initiated weanling Sprague-Dawley rats: a quantitative, phenotypic, and ras p21 protein study. Sills RC; Goldsworthy TL; Sleight SD Toxicol Pathol; 1994; 22(3):270-81. PubMed ID: 7817118 [TBL] [Abstract][Full Text] [Related]
10. The dose-response model for dioxin. Byrd DM; Allen DO; Beamer RL; Besch HR; Bylund DB; Doull J; Fleming WW; Fries A; Guengerich FP; Hornbrook R; Lasagna L; Lum BK; Michaelis EK; Morgan ET; Poland A; Rozman KK; Smith JB; Swanson HI; Waddell W; Wilson JD Risk Anal; 1998 Feb; 18(1):1-2. PubMed ID: 9556441 [No Abstract] [Full Text] [Related]
12. Negative selection in hepatic tumor promotion in relation to cancer risk assessment. Andersen ME; Mills JJ; Jirtle RL; Greenlee WF Toxicology; 1995 Sep; 102(1-2):223-37. PubMed ID: 7482557 [TBL] [Abstract][Full Text] [Related]
13. Receptor-mediated toxicity and implications for risk assessment. Andersen ME; Mills JJ; Fox TR; Goldsworthy TL; Conolly RB; Birnbaum LS Prog Clin Biol Res; 1994; 387():295-310. PubMed ID: 7972254 [No Abstract] [Full Text] [Related]
14. Induction of altered hepatic foci by a mixture of dioxin-like compounds with and without 2,2',4,4',5,5'-hexachlorobiphenyl in female Sprague-Dawley rats. van der Plas SA; Haag-Grönlund M; Scheu G; Wärngård L; van den Berg M; Wester P; Koeman JH; Brouwer A Toxicol Appl Pharmacol; 1999 Apr; 156(1):30-9. PubMed ID: 10101096 [TBL] [Abstract][Full Text] [Related]
15. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD); "dioxin". National Toxicology Program Rep Carcinog; 2002; 10():224-6. PubMed ID: 15340981 [No Abstract] [Full Text] [Related]
16. Estimates of cancer potency of 2,3,7,8-tetrachlorodibenzo(p)dioxin using linear and nonlinear dose-response modeling and toxicokinetics. Simon T; Aylward LL; Kirman CR; Rowlands JC; Budinsky RA Toxicol Sci; 2009 Dec; 112(2):490-506. PubMed ID: 19776211 [TBL] [Abstract][Full Text] [Related]
17. Human response to dioxin: aryl hydrocarbon receptor (AhR) molecular structure, function, and dose-response data for enzyme induction indicate an impaired human AhR. Connor KT; Aylward LL J Toxicol Environ Health B Crit Rev; 2006; 9(2):147-71. PubMed ID: 16613807 [TBL] [Abstract][Full Text] [Related]
19. Modulation of 2,3,7,8-tetrachlorodibenzo-p-dioxin and phenobarbital-induced promotion of hepatocarcinogenesis in rats by the type of diet and vitamin A deficiency. Flodström S; Busk L; Kronevi T; Ahlborg UG Fundam Appl Toxicol; 1991 Feb; 16(2):375-91. PubMed ID: 2055368 [TBL] [Abstract][Full Text] [Related]
20. 2,3,7,8-Tetrachlorodibenzo-p-dioxin. National Toxicology Program Rep Carcinog; 2011; 12():396-8. PubMed ID: 21863101 [No Abstract] [Full Text] [Related] [Next] [New Search]